What is the recommended treatment regimen for leprosy (Hansen disease), including drug choices, dosages, duration, and monitoring, for both paucibacillary and multibacillary disease?

Leprosy Treatment Summary

Treat paucibacillary leprosy with rifampin 600 mg and dapsone 100 mg monthly for 6 months, and multibacillary leprosy with rifampin 600 mg, dapsone 100 mg, and clofazimine 300 mg monthly (plus clofazimine 50 mg daily) for 12 months, following WHO multidrug therapy protocols. 1, 2, 3

Classification and Treatment Duration

The treatment approach depends entirely on disease classification:

• Paucibacillary leprosy: Characterized by vigorous pro-inflammatory immunity with few bacteria, requires 6 months of multidrug therapy 1, 2, 3
• Multibacillary leprosy: Harbors large numbers of bacteria with high levels of anti-M. leprae antibodies, requires 12 months of multidrug therapy 1, 2, 3

Standard WHO Multidrug Therapy Regimens

Paucibacillary Disease (6 months)

• Rifampin: 600 mg once monthly, supervised 2, 3, 4
• Dapsone: 100 mg daily, self-administered 2, 3, 4

Multibacillary Disease (12 months)

• Rifampin: 600 mg once monthly, supervised 2, 3, 4
• Clofazimine: 300 mg once monthly supervised, plus 50 mg daily self-administered 2, 3, 4
• Dapsone: 100 mg daily, self-administered 2, 3, 4

These medications are available free of cost in blister calendar packs at government health facilities in endemic areas 5

Alternative Drug Options

When standard multidrug therapy components become contraindicated, alternative drugs include:

• Ofloxacin (fluoroquinolone) 5
• Minocycline (tetracycline) 5, 6
• Clarithromycin (macrolide) 5
• Moxifloxacin (fluoroquinolone) 6
• Rifabutin (rifamycin alternative) 6

An alternative regimen of monthly moxifloxacin, rifabutin, and minocycline has been successfully used in clinical practice when standard therapy was not suitable 6

Emerging Treatment: Bedaquiline

Bedaquiline monotherapy represents a promising new approach for multibacillary leprosy, showing remarkable efficacy in a 2024 proof-of-concept study 7:

• Dosing: 8 weeks of bedaquiline monotherapy followed by standard WHO multidrug therapy 7
• Efficacy: Cleared M. leprae by 4 weeks of treatment, with improvement in skin lesions by 7 weeks 7
• Safety: All adverse events were grade 1 or 2 7
• This represents a potential breakthrough for patients who cannot tolerate standard therapy or in drug-resistant cases 7

Monitoring and Key Considerations

Treatment Effectiveness

Standard multidrug therapy has proven safe and effective since its introduction in 1982, contributing to a drastic decline in new cases worldwide 2, 5

Drug Resistance

Despite multidrug therapy, resistant strains are emerging, making identification and monitoring of resistance necessary 2

Leprosy Reactions

Critical pitfall: Leprosy reactions during therapy may considerably aggravate the disease course and require additional management 3

Treatment Outcomes

Early treatment frequently results in complete remission without sequelae 3. The lengthy incubation period of 2-6 years (sometimes longer) emphasizes the importance of early case detection 1

Post-Exposure Prophylaxis

National healthcare programs should consider post-exposure prophylaxis for individuals in close contact with affected persons to interrupt transmission and prevent disease progression 1

Special Populations

The disease disproportionately affects marginalized communities, with highest incidence in India, Brazil, and Indonesia 1, 3. In the United States, people born in Oceania have a 1064 times higher rate compared to US-born individuals 8